– Agreement covers supply and support of Miltenyi Biotec Prodigy® platform for the manufacture of Autolus programmed T cell therapies –

London – Autolus Limited (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, and Miltenyi Biotec GmbH (“Miltenyi Biotec”), a global provider of products and services that advance biomedical research and cellular therapy, today announced that they have signed a strategic long-term supply agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy® instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies.

Utilising the state-of-the-art, automated cell processing platform CliniMACS Prodigy®, Autolus has established a GMP production process for its programmed T cell therapies designed to address the challenges of commercial-scale manufacturing. Parallel processing of a large number of patient samples in closed systems is key to achieving economic, scalable and reliable commercial manufacture of T cell therapies.

Dr Christian Itin, CEO of Autolus, said:

“We are delighted to announce our strategic relationship with Miltenyi Biotec, a pioneer in design and engineering of equipment and reagents that support production of cell therapies. This agreement builds on the longstanding collaboration between our companies and leverages our respective leadership positions in programmed T cell therapies, process design, engineering and automation.”

Stefan Miltenyi, President and CEO at Miltenyi Biotec, added:

“Autolus is a leader in the development of programmed T cell therapies. We are therefore delighted that Autolus has chosen our Prodigy platform for the manufacture of its clinical-stage portfolio and we look forward to further demonstrating its utility in the commercial manufacture of advanced T cell therapies.”